Chimeric Therapeutics Limited (CHM.AX) Stock Competitors & Peer Comparison
See (CHM.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHM.AX | A$0.06 | +5.26% | 2.4M | -0.17 | -A$0.34 | N/A |
| CSL.AX | A$121.24 | +2.42% | 56.4B | 12.66 | A$9.30 | +3.62% |
| TLX.AX | A$16.78 | -1.41% | 5.8B | -619.99 | -A$0.03 | N/A |
| MSB.AX | A$2.05 | +0.25% | 2.7B | -13.79 | -A$0.15 | N/A |
| NEU.AX | A$16.72 | -5.27% | 2.2B | 72.37 | A$0.23 | N/A |
| PYC.AX | A$1.56 | -7.44% | 941.6M | -35.42 | -A$0.05 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | 6.14 | A$0.10 | N/A |
| CUV.AX | A$10.24 | -1.73% | 517.2M | 15.92 | A$0.64 | +0.49% |
| RAC.AX | A$2.21 | +0.45% | 447M | -110.14 | -A$0.02 | N/A |
| SPL.AX | A$0.74 | +4.23% | 298.9M | 112.70 | A$0.01 | N/A |
Stock Comparison
CHM.AX vs CSL.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, CSL.AX has a market cap of 56.4B. Regarding current trading prices, CHM.AX is priced at A$0.06, while CSL.AX trades at A$121.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas CSL.AX's P/E ratio is 12.66. In terms of profitability, CHM.AX's ROE is +28.45%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, CHM.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check CSL.AX's competition here
CHM.AX vs TLX.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, TLX.AX has a market cap of 5.8B. Regarding current trading prices, CHM.AX is priced at A$0.06, while TLX.AX trades at A$16.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas TLX.AX's P/E ratio is -619.99. In terms of profitability, CHM.AX's ROE is +28.45%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, CHM.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check TLX.AX's competition here
CHM.AX vs MSB.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, MSB.AX has a market cap of 2.7B. Regarding current trading prices, CHM.AX is priced at A$0.06, while MSB.AX trades at A$2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas MSB.AX's P/E ratio is -13.79. In terms of profitability, CHM.AX's ROE is +28.45%, compared to MSB.AX's ROE of -0.16%. Regarding short-term risk, CHM.AX is less volatile compared to MSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check MSB.AX's competition here
CHM.AX vs NEU.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, NEU.AX has a market cap of 2.2B. Regarding current trading prices, CHM.AX is priced at A$0.06, while NEU.AX trades at A$16.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas NEU.AX's P/E ratio is 72.37. In terms of profitability, CHM.AX's ROE is +28.45%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, CHM.AX is less volatile compared to NEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check NEU.AX's competition here
CHM.AX vs PYC.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, PYC.AX has a market cap of 941.6M. Regarding current trading prices, CHM.AX is priced at A$0.06, while PYC.AX trades at A$1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas PYC.AX's P/E ratio is -35.42. In terms of profitability, CHM.AX's ROE is +28.45%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, CHM.AX is less volatile compared to PYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check PYC.AX's competition here
CHM.AX vs OPT.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, CHM.AX is priced at A$0.06, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas OPT.AX's P/E ratio is 6.14. In terms of profitability, CHM.AX's ROE is +28.45%, compared to OPT.AX's ROE of -3.12%. Regarding short-term risk, CHM.AX is less volatile compared to OPT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check OPT.AX's competition here
CHM.AX vs CUV.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, CUV.AX has a market cap of 517.2M. Regarding current trading prices, CHM.AX is priced at A$0.06, while CUV.AX trades at A$10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas CUV.AX's P/E ratio is 15.92. In terms of profitability, CHM.AX's ROE is +28.45%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, CHM.AX is less volatile compared to CUV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check CUV.AX's competition here
CHM.AX vs RAC.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, RAC.AX has a market cap of 447M. Regarding current trading prices, CHM.AX is priced at A$0.06, while RAC.AX trades at A$2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas RAC.AX's P/E ratio is -110.14. In terms of profitability, CHM.AX's ROE is +28.45%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, CHM.AX is less volatile compared to RAC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check RAC.AX's competition here
CHM.AX vs SPL.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, SPL.AX has a market cap of 298.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while SPL.AX trades at A$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas SPL.AX's P/E ratio is 112.70. In terms of profitability, CHM.AX's ROE is +28.45%, compared to SPL.AX's ROE of -0.16%. Regarding short-term risk, CHM.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check SPL.AX's competition here
CHM.AX vs OCC.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, OCC.AX has a market cap of 159.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while OCC.AX trades at A$0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas OCC.AX's P/E ratio is -26.67. In terms of profitability, CHM.AX's ROE is +28.45%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, CHM.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check OCC.AX's competition here
CHM.AX vs DXB.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, DXB.AX has a market cap of 150.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while DXB.AX trades at A$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas DXB.AX's P/E ratio is -5.01. In terms of profitability, CHM.AX's ROE is +28.45%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, CHM.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check DXB.AX's competition here
CHM.AX vs ATH.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ATH.AX has a market cap of 141.4M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ATH.AX trades at A$0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ATH.AX's P/E ratio is -382.35. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, CHM.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check ATH.AX's competition here
CHM.AX vs ACW.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ACW.AX has a market cap of 126.4M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ACW.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ACW.AX's P/E ratio is -5.90. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, CHM.AX is less volatile compared to ACW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check ACW.AX's competition here
CHM.AX vs PAA.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, CHM.AX's ROE is +28.45%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, CHM.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check PAA.AX's competition here
CHM.AX vs RCE.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, RCE.AX has a market cap of 108.4M. Regarding current trading prices, CHM.AX is priced at A$0.06, while RCE.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas RCE.AX's P/E ratio is -4.12. In terms of profitability, CHM.AX's ROE is +28.45%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, CHM.AX is less volatile compared to RCE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check RCE.AX's competition here
CHM.AX vs ILA.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ILA.AX has a market cap of 93.8M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ILA.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ILA.AX's P/E ratio is -12.02. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, CHM.AX is more volatile compared to ILA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check ILA.AX's competition here
CHM.AX vs ALA.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ALA.AX has a market cap of 83.4M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ALA.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ALA.AX's P/E ratio is -9.70. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, CHM.AX is more volatile compared to ALA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check ALA.AX's competition here
CHM.AX vs IMM.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, IMM.AX has a market cap of 82.5M. Regarding current trading prices, CHM.AX is priced at A$0.06, while IMM.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas IMM.AX's P/E ratio is -0.98. In terms of profitability, CHM.AX's ROE is +28.45%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, CHM.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check IMM.AX's competition here
CHM.AX vs ATX.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ATX.AX has a market cap of 77M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ATX.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ATX.AX's P/E ratio is -8.67. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ATX.AX's ROE of -0.19%. Regarding short-term risk, CHM.AX is less volatile compared to ATX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check ATX.AX's competition here
CHM.AX vs PAR.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, PAR.AX has a market cap of 73.7M. Regarding current trading prices, CHM.AX is priced at A$0.06, while PAR.AX trades at A$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas PAR.AX's P/E ratio is -2.33. In terms of profitability, CHM.AX's ROE is +28.45%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, CHM.AX is less volatile compared to PAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check PAR.AX's competition here
CHM.AX vs PTX.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, PTX.AX has a market cap of 70.5M. Regarding current trading prices, CHM.AX is priced at A$0.06, while PTX.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas PTX.AX's P/E ratio is -7.37. In terms of profitability, CHM.AX's ROE is +28.45%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, CHM.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check PTX.AX's competition here
CHM.AX vs BIO.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, BIO.AX has a market cap of 66.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while BIO.AX trades at A$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas BIO.AX's P/E ratio is 69.05. In terms of profitability, CHM.AX's ROE is +28.45%, compared to BIO.AX's ROE of +0.18%. Regarding short-term risk, CHM.AX and BIO.AX have similar daily volatility (1.68).Check BIO.AX's competition here
CHM.AX vs AVE.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, AVE.AX has a market cap of 62.3M. Regarding current trading prices, CHM.AX is priced at A$0.06, while AVE.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas AVE.AX's P/E ratio is -14.79. In terms of profitability, CHM.AX's ROE is +28.45%, compared to AVE.AX's ROE of -2.58%. Regarding short-term risk, CHM.AX is less volatile compared to AVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check AVE.AX's competition here
CHM.AX vs IMU.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, IMU.AX has a market cap of 56.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while IMU.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas IMU.AX's P/E ratio is -0.99. In terms of profitability, CHM.AX's ROE is +28.45%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, CHM.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check IMU.AX's competition here
CHM.AX vs ENP.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ENP.AX has a market cap of 52.2M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ENP.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ENP.AX's ROE of -0.68%. Regarding short-term risk, CHM.AX is less volatile compared to ENP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check ENP.AX's competition here
CHM.AX vs RAD.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, RAD.AX has a market cap of 49.7M. Regarding current trading prices, CHM.AX is priced at A$0.06, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas RAD.AX's P/E ratio is -1.01. In terms of profitability, CHM.AX's ROE is +28.45%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, CHM.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check RAD.AX's competition here
CHM.AX vs BOT.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, BOT.AX has a market cap of 41.8M. Regarding current trading prices, CHM.AX is priced at A$0.06, while BOT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas BOT.AX's P/E ratio is -0.62. In terms of profitability, CHM.AX's ROE is +28.45%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, CHM.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check BOT.AX's competition here
CHM.AX vs NOX.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, NOX.AX has a market cap of 28.3M. Regarding current trading prices, CHM.AX is priced at A$0.06, while NOX.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas NOX.AX's P/E ratio is -4.90. In terms of profitability, CHM.AX's ROE is +28.45%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, CHM.AX is more volatile compared to NOX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check NOX.AX's competition here
CHM.AX vs LCT.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, CHM.AX is priced at A$0.06, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, CHM.AX's ROE is +28.45%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, CHM.AX is more volatile compared to LCT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check LCT.AX's competition here
CHM.AX vs MEM.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, MEM.AX has a market cap of 21.6M. Regarding current trading prices, CHM.AX is priced at A$0.06, while MEM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas MEM.AX's P/E ratio is -3.33. In terms of profitability, CHM.AX's ROE is +28.45%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, CHM.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check MEM.AX's competition here
CHM.AX vs 1AI.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, 1AI.AX has a market cap of 20.6M. Regarding current trading prices, CHM.AX is priced at A$0.06, while 1AI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, CHM.AX's ROE is +28.45%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, CHM.AX is more volatile compared to 1AI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check 1AI.AX's competition here
CHM.AX vs NSB.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, NSB.AX has a market cap of 20M. Regarding current trading prices, CHM.AX is priced at A$0.06, while NSB.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas NSB.AX's P/E ratio is -4.14. In terms of profitability, CHM.AX's ROE is +28.45%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, CHM.AX is less volatile compared to NSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check NSB.AX's competition here
CHM.AX vs NC6.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, NC6.AX has a market cap of 20M. Regarding current trading prices, CHM.AX is priced at A$0.06, while NC6.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas NC6.AX's P/E ratio is -7.38. In terms of profitability, CHM.AX's ROE is +28.45%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, CHM.AX is more volatile compared to NC6.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check NC6.AX's competition here
CHM.AX vs EZZ.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, EZZ.AX has a market cap of 19.8M. Regarding current trading prices, CHM.AX is priced at A$0.06, while EZZ.AX trades at A$0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas EZZ.AX's P/E ratio is 6.86. In terms of profitability, CHM.AX's ROE is +28.45%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, CHM.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check EZZ.AX's competition here
CHM.AX vs KZA.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, CHM.AX's ROE is +28.45%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, CHM.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check KZA.AX's competition here
CHM.AX vs BTC.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, BTC.AX has a market cap of 18M. Regarding current trading prices, CHM.AX is priced at A$0.06, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas BTC.AX's P/E ratio is -21.89. In terms of profitability, CHM.AX's ROE is +28.45%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, CHM.AX is more volatile compared to BTC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check BTC.AX's competition here
CHM.AX vs MDC.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas MDC.AX's P/E ratio is -7.07. In terms of profitability, CHM.AX's ROE is +28.45%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, CHM.AX is more volatile compared to MDC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check MDC.AX's competition here
CHM.AX vs AGN.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, AGN.AX has a market cap of 14.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while AGN.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas AGN.AX's P/E ratio is -1.44. In terms of profitability, CHM.AX's ROE is +28.45%, compared to AGN.AX's ROE of -1.84%. Regarding short-term risk, CHM.AX is less volatile compared to AGN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check AGN.AX's competition here
CHM.AX vs PAB.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, PAB.AX has a market cap of 13.3M. Regarding current trading prices, CHM.AX is priced at A$0.06, while PAB.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas PAB.AX's P/E ratio is -3.29. In terms of profitability, CHM.AX's ROE is +28.45%, compared to PAB.AX's ROE of -4.06%. Regarding short-term risk, CHM.AX is less volatile compared to PAB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check PAB.AX's competition here
CHM.AX vs BNO.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, CHM.AX is priced at A$0.06, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, CHM.AX's ROE is +28.45%, compared to BNO.AX's ROE of +0.47%. Regarding short-term risk, CHM.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check BNO.AX's competition here
CHM.AX vs CMB.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, CMB.AX has a market cap of 10.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while CMB.AX trades at A$0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas CMB.AX's P/E ratio is -6.29. In terms of profitability, CHM.AX's ROE is +28.45%, compared to CMB.AX's ROE of -1.62%. Regarding short-term risk, CHM.AX is more volatile compared to CMB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check CMB.AX's competition here
CHM.AX vs IMC.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, IMC.AX has a market cap of 8.5M. Regarding current trading prices, CHM.AX is priced at A$0.06, while IMC.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas IMC.AX's P/E ratio is -1.77. In terms of profitability, CHM.AX's ROE is +28.45%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, CHM.AX is less volatile compared to IMC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check IMC.AX's competition here
CHM.AX vs IXC.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, IXC.AX has a market cap of 7.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while IXC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas IXC.AX's P/E ratio is -8.57. In terms of profitability, CHM.AX's ROE is +28.45%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, CHM.AX is more volatile compared to IXC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check IXC.AX's competition here
CHM.AX vs VBS.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, VBS.AX has a market cap of 6.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while VBS.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas VBS.AX's P/E ratio is -4.92. In terms of profitability, CHM.AX's ROE is +28.45%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, CHM.AX is less volatile compared to VBS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check VBS.AX's competition here
CHM.AX vs TRP.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, TRP.AX has a market cap of 6M. Regarding current trading prices, CHM.AX is priced at A$0.06, while TRP.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas TRP.AX's P/E ratio is -1.57. In terms of profitability, CHM.AX's ROE is +28.45%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, CHM.AX is less volatile compared to TRP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check TRP.AX's competition here
CHM.AX vs ZLD.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ZLD.AX's P/E ratio is -1.58. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ZLD.AX's ROE of +0.81%. Regarding short-term risk, CHM.AX is less volatile compared to ZLD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check ZLD.AX's competition here
CHM.AX vs BIT.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, BIT.AX has a market cap of 4.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas BIT.AX's P/E ratio is -9.09. In terms of profitability, CHM.AX's ROE is +28.45%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, CHM.AX is less volatile compared to BIT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check BIT.AX's competition here
CHM.AX vs ACR.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ACR.AX has a market cap of 4.8M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ACR.AX's P/E ratio is -1.09. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, CHM.AX is more volatile compared to ACR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check ACR.AX's competition here
CHM.AX vs BGT.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, BGT.AX has a market cap of 4.6M. Regarding current trading prices, CHM.AX is priced at A$0.06, while BGT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas BGT.AX's P/E ratio is -2.39. In terms of profitability, CHM.AX's ROE is +28.45%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, CHM.AX is more volatile compared to BGT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check BGT.AX's competition here
CHM.AX vs RGS.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, CHM.AX is priced at A$0.06, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, CHM.AX's ROE is +28.45%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, CHM.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CHM.AX.Check RGS.AX's competition here
CHM.AX vs CYP.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, CYP.AX has a market cap of 3.4M. Regarding current trading prices, CHM.AX is priced at A$0.06, while CYP.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas CYP.AX's P/E ratio is -0.45. In terms of profitability, CHM.AX's ROE is +28.45%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, CHM.AX is more volatile compared to CYP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check CYP.AX's competition here
CHM.AX vs 1AD.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, 1AD.AX has a market cap of 2.4M. Regarding current trading prices, CHM.AX is priced at A$0.06, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas 1AD.AX's P/E ratio is -0.26. In terms of profitability, CHM.AX's ROE is +28.45%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, CHM.AX is more volatile compared to 1AD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check 1AD.AX's competition here
CHM.AX vs ANR.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, ANR.AX has a market cap of 2.1M. Regarding current trading prices, CHM.AX is priced at A$0.06, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas ANR.AX's P/E ratio is -1.25. In terms of profitability, CHM.AX's ROE is +28.45%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, CHM.AX is more volatile compared to ANR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check ANR.AX's competition here
CHM.AX vs EX1.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, CHM.AX is priced at A$0.06, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, CHM.AX's ROE is +28.45%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, CHM.AX is more volatile compared to EX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check EX1.AX's competition here
CHM.AX vs HXL.AX Comparison July 2026
CHM.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHM.AX stands at 2.4M. In comparison, HXL.AX has a market cap of 542.9K. Regarding current trading prices, CHM.AX is priced at A$0.06, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHM.AX currently has a P/E ratio of -0.17, whereas HXL.AX's P/E ratio is -0.58. In terms of profitability, CHM.AX's ROE is +28.45%, compared to HXL.AX's ROE of -0.14%. Regarding short-term risk, CHM.AX is more volatile compared to HXL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CHM.AX.Check HXL.AX's competition here